Rational design of Salmonella recombinant vaccines

Cheminay, Cédric; Hensel, Michael

doi:10.1016/j.ijmm.2007.08.006

Cited by 58 publications

(48 citation statements)

References 108 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a control, spleen cells were stimulated with 1 g ml Ϫ1 concanavalin A (Sigma, Deisenhofen, Germany) without the addition of DC. After 48 h of coincubation, the proliferation was measured by 3 H uptake for an additional 24 h. All experiments were performed in triplicate and at least three biological replicates were performed.…”

Section: Methodsmentioning

confidence: 99%

“…Moreover, the use of live attenuated Salmonella to deliver recombinant antigens to the immune system is an attractive strategy for the construction of multivalent vaccines (17). Salmonella-based vaccines provide a number of advantages over other antigen delivery strategies, including low cost of production, oral delivery, the absence of animal products, genetic stability, and safety (3). In addition, Salmonella vaccines delivering heterologous antigens elicit efficient immune responses via stimulation of both innate and adaptive immunity (3).…”

mentioning

confidence: 99%

“…Salmonella-based vaccines provide a number of advantages over other antigen delivery strategies, including low cost of production, oral delivery, the absence of animal products, genetic stability, and safety (3). In addition, Salmonella vaccines delivering heterologous antigens elicit efficient immune responses via stimulation of both innate and adaptive immunity (3). The availability of S. enterica serovar Typhimurium for preclinical work in mouse models and favorable clinical experience with the live attenuated vaccines S. enterica serovar Typhi Ty21a, CVD908, and CVD909 (20) further facilitate the development of Salmonella-based vaccination approaches.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens

Hegazy

Metelitsa

et al. 2012

Infect Immun

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens

Hegazy

Metelitsa

et al. 2012

Infect Immun

Self Cite

View full text Add to dashboard Cite

“…Currently two licensed vaccines against Salmonella are in use globally: Vi polysaccharide vaccine and Ty21a live attenuated vaccine [69]. Vivotif Berna ® is an attenuated live Salmonella Typhi Ty21a strain, generated by chemical mutagenesis of parental virulent strain of Salmonella Typhi Ty21 using nitrosoguanidine [70].…”

Section: Vaccinesmentioning

confidence: 99%

Vi antigen of Salmonella enetrica serovar Typhi — biosynthesis, regulation and its use as vaccine candidate

Kaur

Jain

2012

Open Life Sciences

View full text Add to dashboard Cite

Vi capsular polysaccharide (Vi antigen) was first identified as the virulence antigen of Salmonella enterica serovar Typhi (S. Typhi), the causative agent of typhoid fever in humans. The presence of Vi antigen differentiates S. Typhi from other serovars of Salmonella. Vi antigen is a linear polymer consisting of α-1,4-linked-N-acetyl-galactosaminuronate, whose expression is controlled by three chromosomal loci, namely viaA, viaB and ompB. Both viaA and viaB region are present on Salmonella Pathogenicity Island-7, a large, mosaic, genetic island. The viaA region encodes a positive regulator and the viaB locus is composed of 11 genes designated tviA-tviE (for Vi biosyhthesis), vexA-vexE (for Vi antigen export) and ORF 11. Vi polysaccharide is synthesized from UDP-N-acetyl glucosamine in a series of steps requiring TviB, TviC, and TviE, and regulation of Vi polysaccharide synthesis is controlled by two regulatory systems, rscB-rscC (viaA locus) and ompR-envZ (ompB locus), which respond to changes in osmolarity. This antigen is highly immunogenic and has been used for the formulation of one of the currently available vaccines against typhoid. Despite advancement in the area of vaccinology, its pace of progress needs to be accelerated and effective control programmes will be needed for proper disease management.

show abstract

“…Although licensed, it is considered unsuitable for mass immunization and no longer in use (Garmony et al 2002). The other licensed vaccines against Salmonella in use globally are Vi polysaccharide vaccine and Ty21a live attenuated vaccine (Cheminay & Hensel 2008). Both these vaccines are well tolerated but are only moderately protective (Ivanoff et al 1994;Keitel et al 1994;Merican 1997;Levine et al 1999;Allam et al 2011).…”

Section: Introductionmentioning

confidence: 99%

Protection against experimental salmonellosis by recombinant 49 kDa OMP of Salmonella enterica serovar Typhi: biochemical aspects

Kaur

Jain

2013

Biologia

View full text Add to dashboard Cite

Typhoid fever is systemic illness caused by Salmonella enterica serovar Typhi (S. Typhi) in humans. Increasing multidrug resistant strains of S. Typhi and limited effect of available vaccines has necessitated exploring of new immunogens for protection against it. Earlier studies have shown that a crude preparation of outer membrane proteins (OMPs) of S. Typhi evokes strong immune response and induces a protective immunity against infection caused by diverse Gram-negative bacteria. In the present study we have evaluated the protective effect of a purified recombinant 49 kDa (r49kDa) OMP of S. Typhi alone or along with alum or complete Freund's adjuvant, against a challenge by S. Typhi (0.4 × 50% lethal dose) by biochemical estimation of serum enzymes and oxidative stress enzymes in Swiss albino mice. There was a decrease in activity of alanine aminotransferase by 14.28%, 38.09%, 23.80%; aspartate aminotransferase by 6.25%, 25%, 16.25%; lipid peroxidation by 4.34%, 18.84%, 11.59%; and catalase by 8%, 14%, 10%, respectively, whereas increase in activity of reduced glutathione by 33.33%, 61.11%, 44.44%; glutathione peroxidase by 7%, 16%, 10%; and glutathione reductase by 8%, 20%, 12%, respectively, as compared to control animals challenged with bacteria without pre-immunization. The results indicated that immunization of mice with r49kDa OMP alone or in combination with adjuvants protected and normalized the liver. It reduces the development of oxidative stress in mice against Salmonella infection and the risk of getting typhoid. These results represent an additional supplement to our earlier reported data on protective immunity evoked by this protein.

show abstract

Rational design of Salmonella recombinant vaccines

Cited by 58 publications

References 108 publications

Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens

Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens

Vi antigen of Salmonella enetrica serovar Typhi — biosynthesis, regulation and its use as vaccine candidate

Protection against experimental salmonellosis by recombinant 49 kDa OMP of Salmonella enterica serovar Typhi: biochemical aspects

Contact Info

Product

Resources

About